Heska Corp. plans to manufacture and market a proprietary, sublingual therapy treatment for pets suffering with allergies, the company announced today.
The Loveland, Colo.-based company will introduce the new product at the onset of the allergy season.
Dr. Mary Morris and Associates LLC of La Crosse, Wis., developed the therapy treatment to expand treatment options for allergic diseases in people and animals, and partnered with Heska Corp. to manufacture and market the technology to the pet market.
“Sublingual therapy offers a convenient alternative to subcutaneous injection, thereby enhancing the likelihood of pet owner compliance,” said Michael McGinley, president and chief operating officer of Heska.
The product has undergone substantial testing over the past three years, according to Heska.
Heska will manufacture the new allergy treatment product at its Des Moines, Iowa, facility, where the company moved its allergy immunotherapy manufacturing in 2011.